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Dcharacteristics to assist in appropriate patient selection.
The results of the present study should provide surgeons
and interventional cardiologists with a framework from
which to explore alternative strategies for treating patients
with ductal-dependent pulmonary circulation.
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Dr Ross Ungerleider (Winston-Salem, NC). Very nice. You are
a cardiologist, right?
Dr Rubio. I am.
Dr Ungerleider. Give him the applause. It must take a lot of
courage to come to a surgical meeting.
Dr Rubio. It is a little intimidating, but we will see.
Dr Ungerleider. Hang onto that courage right now. I have a
couple questions for you.
It is interesting. If you put it in perspective, the Blalock-Taussig
shunt was probably considered by many to be what started cardiac
surgery, and then prostaglandins came along, and they took the
word ‘‘emergency’’ out of shunting. Now cardiologists are coming
along andmight be taking theword ‘‘surgical’’ out of shunting.My
first question for you really centers on that. We continue to evolve
new methods to approach old problems, and we call this innova-
tion. Although, as you mentioned, the concept of ductal stenting
is not new, the application of ductal stents as a method to
palliate patients who would more traditionally be treated withThe Journal of Thoracic and Caaortopulmonary shunts is a little bit novel. Now, without innova-
tive thinking, we would just keep doing what we have always
done and keep getting what we have always gotten; thus, I applaud
you for this effort. However, philosophically and ethically, it does
beg a question. When does innovation become human experimen-
tation? More specifically, how did your patients give consent?
Were they given surgical and interventional options? Did they
know that this was a nonstandard option?Who did the consent pro-
cess? Were the decisions made by the entire team, and, in fact, did
you need to have institutional review board approval?
Dr Rubio. Thank you for the questions, Dr Ungerleider. The
discussion about the option for an interventional approach instead
of a surgical approach is a decision that is made in a general con-
ference with consultation from the cardiothoracic surgeons, cardi-
ologists, and interventional cardiologists. It is a team decision that
is made, and that team decision is taken to the family as an option.
The surgical reference standard, what I call the reference standard,
the option of surgery for systemic to pulmonary arterial communi-
cation, is always the one presented first. Second, if other comorbid-
ities are present that would make the patient a less than suitable
candidate for bypass in case it might be needed, the discussion
of a nontraditional—I do not like to use the word ‘‘experimental,’’
because this is not an experimental use, but rather the nontradi-
tional use of coronary stenting, in this case stenting of the duc-
tus—is given to the parents. Expectations are also given as to
what type of follow-up will be needed.
Dr Ungerleider. I am just curious. Do you need institutional re-
view board approval in your institution to do nonstandard therapy?
Dr Rubio. No, we do not.
Dr Ungerleider. The next question—you did so well, I am
going to give you another one. This is more related to the indica-
tions for this. You did mention Gibbs’ pioneering work in this, and,
actually a member of this organization, Len Bailey, writing an
editorial about that in 1999, heralded your work by calling this a
‘‘wannabe’’ Blalock-Taussig shunt. However, the prevailing
thought at that time was that coronary stents were really not suited
for the somewhat tortuous and anatomically more difficult ducti
you see in the ductal-dependent lesions that are not hypoplastic
left heart syndrome. You very nicely listed the potential complica-
tions of the Blalock-Taussig or aortopulmonary shunt. You did not
really list them for ductal stents. Now you only had 13 or so—your
numbers are small—but the complications or, as I like to call them,
the consequences, of ductal stents have been well written. They
have included malposition, restenosis, the need sometimes for
multiple stents, erosion, the loss of vessels in the leg that might
one day be necessary, and the technical demands. Those have
been well described. Thus, the question I have for you really re-
volves around the important decision making as we enter this
era of collaboration among cardiologists, interventional cardiolo-
gists, and surgeons, and you certainly seem to have a tendency to
place these stents in patients with pulmonary atresia, so the ques-
tion is, who are the patients who seem most suitable for this? Are
they the patients with pulmonary atresia and a ventricular septal
defect or those with pulmonary atresia and an intact septum?
Tell us from your experience, as we start to consider this as an op-
tion, which of the patients would be the ones who we really should
be thinking most about this?
Dr Rubio. With regard to the ideal patient for this, from my
experience and the experience we have had at our institution, therdiovascular Surgery c Volume 147, Number 1 401
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intact ventricular septum. These patients typically have a hypo-
plastic right ventricle. However, if they are able to demonstrate
with echocardiographic evidence a tricuspid valve annulus that
is<3 standard deviations away from the norm or we are able to
delineate that there is a bipartite right ventricle, a pulmonary at-
retic valve that is reachable by cardiac catheterization safely,
and an ability to establish prograde flow from the right ventricle
into the pulmonary artery, we believe that those patients will be
better candidates for prograde deployment of these coronary
stents. Taking into account the many complications and quirks
that these patients with pulmonary atresia have regarding their
ducti, it does take a certain skill set to be able to be comfortable
in deploying these stents. Stents have been deployed down the de-
scending aorta. They have been deployed into the pulmonary
valve. They have been known, if you are not careful, to exclude
1 of the branch pulmonary arteries. Vascular access is always a
problem. Retrograde approaches are the most difficult and the
ones associated with the most vascular occlusions. The prograde
approach is not as complicated. Those would be the ideal patients.
Dr Ungerleider. It all sounds scary. I still like the idea of an
outflow patch and a shunt. Thank you for sharing this. This is a
very innovative technique that we will all pay attention to.
Dr John Chen (Honolulu, Hawaii). Dr Rubio, you should be
congratulated on your excellent results, remembering that most
of these patients, I presume, weigh 3 kg. I guess my question
is have you followed up these patients or had the opportunity to
follow-up these patients in the long term as to what happens to
these shunts and have you come across a situation in which you
had to ligate a shunt later on that had been stented? What do
you do in that situation?
Dr Rubio. We have been able to follow-up a few of these pa-
tients in the long-term setting, meaning that they have reached
about 1 year of age. In particular, a couple of the patients with pul-
monary atresia and an intact septum in which the pulmonary valve
was able to be perforated and allow for growth, the stents, when we
are bringing them back into the catheter laboratory, have had a
neointimal proliferation within the stent, which is a well-known
complication. However, it has been auto-amputating itself, and
the hope is that the natural course of this neointimal proliferation
will begin to take the stent out of the equation of the additional pul-
monary blood supply and not sacrifice significant saturation. The
ligation I will have to leave to my surgeons, but it is common
that, if we have to go to a Glen palliation at 6 months of age for
a right ventricle that is not growing or if it is used in a patient
who does not have the ability to have 2 sources of pulmonary blood
flow, I do believe that the ductus is ligated with the stent in place.
They crimp down the stent so that no further flow occurs.
Dr Chen. Ross, you just tie this thing off and crush the stent?
What do you do with this?
DrUngerleider.You can crush them. They do erode sometimes.
Usually, not that much flow occurs. What does happen, and it
worries me, but any time we do new things, we have to be willing
to accept the consequences of that. Anything we do has conse-
quences. You might have to do some arch reconstructions in pa-
tients who would not ordinarily undergo an arch reconstruction,
but for the most part, you can just crimp these stents. We have
also cut through them sometimes when we are doing a Fontan402 The Journal of Thoracic and Cardiovascular Surgfor patients who have had stents in the pulmonary arteries. It is
easy to cut through them, so they are there. Whether we should
be putting them in this location or if we. . One of the points I
would just say is, if we move to value-based care in which we
are not being measured by relative value units but by what is the
best we can do in using the resources, the real questionwe are going
to be asking, because we will all get paid whether we do an inter-
ventional stent or a surgical shunt (themoney comes in as revenue),
and we want to make sure that we have value, more revenue, and
less cost. The real question that we are going to be addressing
one day is what is the best time to use these and which of the pa-
tients we should not use them for, but it is a very fascinating idea.
Dr Gordon Cohen (Seattle, Wash).As one of the surgeons who
manages these stents, they are very easy to manage, as Ross said.
We can just put a (ligate) clip across it, and if you are doing a bidi-
rectional Glen as a second-stage palliation, it does not get in the
way at all. It is just like ligating the ductus at the beginning of
any other operation, but in these cases, we just use a ligate clip,
and it is quite easy to deal with.
As far as Ross’ questions go, if we think back to the history of
the Blalock-Taussig shunts when Mark DeLaval first started doing
the modified Blalock-Taussig shunt and using a Gore-Tex tube to
do it, he did not have institutional review board approval. One day
he had to make a decision that this was, in his opinion, a better
operation, and it quickly became the reference standard. If we
think about what the goals are in terms of doing a systemic to pul-
monary shunt, really all we are doing is re-creating the ductus ar-
teriosus. We cannot leave a patient taking prostaglandin for 6
months, so we are surgically re-creating the ductus arteriosus. In
this case, we are just replacing the prostaglandin with a stent,
and, frankly, it is very easy to manage. Also, what is nice about
it is that when you come back for the second-stage operation, there
is no risk of injuring the heart on re-entry; there are no adhesions to
manage. If you want to use autologous pericardium to do a part of
your reconstruction, it is easily available because it has not been
adhered down to the heart. Thus, frankly, it makes everything
very, very easy moving forward. The other point is, if you look
in the Society of Thoracic Surgeons database, the outcomes
from modified Blalock-Taussig shunts have not been so great.
There is a pretty high mortality rate associated with it, and it is
actually one of the higher mortality rate operations we do. This
is a much less eventful procedure for the patient to undergo.
They get the stent placed in the ductus. They tolerate it really quite
well, and there is no big issue with it acutely. As Agustin presented
to you, the long-term consequences are actually pretty easy to
manage as well. I think in our institution actually we are moving
toward it becoming, really, our primary intervention when a sys-
temic to pulmonary artery shunt is needed.
Dr Pranava Sinha (Washington, DC). I congratulate you on the
excellent outcomes of the ductal stent, which are much better than
those in the previous reports in which there was a very high inci-
dence of ipsilateral branch pulmonary artery problems.
I have 2 questions for you. One is, do you attribute this remark-
able result to just pure patient selection or has advancement
occurred in the technical aspect of the stenting? My second ques-
tion to you is, in your abstract, I noticed an unusually long interval
between stage 1 and stage 2—a mean of 245 days—which seems
to be longer than usual. The longer you basically stay with a stentery c January 2014
McMullan et al Congenital Heart Diseaseor a shunt, the more complications you are going to see. Can you
comment on that?
Dr Rubio. Regarding your first question, I think most of this is
patient selection. We are very rigorous about choosing which pa-
tient would benefit best from ductal stenting. We are also very
careful with deciding—it has occurred for some patients in the pul-
monary atresia group that we have noticed that the ductus arterio-
sus insertion site is not at the bifurcation point but rather is more
off to the right branch pulmonary artery or the left branch pulmo-
nary artery, where you will have a significant issue with perfusion
to 1 of the lungs. We are very careful with that. Usually, if that is
the case, we see that on the first angiogram within the ductus arte-
riosus, and we refer those patients to surgery.
Regarding your second question, that was an observation we
also made. We are not really sure why it was such a long time
difference between stage 1 and stage 2.The Journal of Thoracic and CaDr Sinha. Because I am looking at some data from our institu-
tion, and our median interstage interval has been in the range of
145 days.
Dr Rubio. There are certain patients that we, for geographic
reasons—we cover Alaska and Montana and Idaho—we
frequently do not get to them within the ideal time period that
we would like because of extraneous issues that we have to deal
with, so that skews some of the numbers, but I think for most of
the patients, especially those undergoing single ventricle pallia-
tion, those patients are brought in in more of a standard time,
with their second stage palliation occurring around 4.5 to 5 months
of age. Our numbers are a little bit skewed also, because some of
the patients have been able to potentially grow part of their right
ventricle or have these 2 sources of pulmonary blood flow and
remain stable, but it is something that we will be looking at in
the future.rdiovascular Surgery c Volume 147, Number 1 403
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